Table 6.

AMACR (5p13) haplotypes and their association with prostate cancer risk.

Haplotype*	Cases (%)	Controls (%)	Crude OR (95% CI)	P value	Adjusted OR(95% CI)a	P value
12345-1[AGCAA]	147 (37.9)	116 (34.3)	Ref.		Ref.
12345-2[AGCGG]	116 (29.9)	103 (30.5)	0.89 (0.62–1.27)	0.5208	0.95 (0.60–1.50)	0.8205
12345-3[ATCGG]	56 (14.4)	47 (13.9)	0.94 (0.60–1.49)	0.7919	1.14 (0.62–2.10)	0.6743
12345-4[GGTGG]	33 (8.5)	39 (11.5)	0.67 (0.40–1.13)	0.1306	0.59 (0.31–1.13)	0.1108
12345-5[GGCGG]	11 (2.8)	20 (5.9)	0.43 (0.20–0.94)	0.0348	0.41 (0.17–1.00)	0.0489
12345-6[AGTGG]	18 (4.6)	9 (2.7)	1.58 (0.68–3.64)	0.2849	0.97 (0.35–2.74)	0.9603
12345-7[GGCAA]	7 (1.8)	3 (0.9)	1.84 (0.47–7.28)	0.3839	1.54 (0.28–8.36)	0.6190
Haplotype pair
12-2 [GG]
0 copies	145 (74.7)	110 (65.1)	Ref.		Ref.
1 or 2 copies	49 (25.3)	59 (34.9)	0.63 (0.40–0.99)	0.0455	0.51 (0.29–0.90)	0.0199
14-3 [GG]
0 copies	153 (78.9)	112 (66.3)	Ref.		Ref.
1 or 2 copies	41 (21.1)	57 (33.7)	0.53 (0.33 –0.84)	0.0074	0.43 (0.24–0.77)	0.0047
15-3 [GG]
0 copies	150 (77.3)	112 (66.3)	Ref.		Ref.
1 or 2 copies	44 (22.7)	57 (33.7)	0.58 (0.36–0.92)	0.0197	0.47 (0.27 –0.84)	0.0104
145-3 [GGG]
0 copies	150 (77.3)	112 (66.3)	Ref.		Ref.
1 or 2 copies	44 (22.7)	57 (33.7)	0.58 (0.36–0.92)	0.0197	0.47 (0.27 –0.84)	0.0104
1245-4 [GGGG]
0 copies	151 (77.8)	113 (66.9)	Ref.		Ref.
1 or 2 copies	43 (22.2)	56 (33.1)	0.57 (0.36–0.92)	0.0199	0.48 (0.27 –0.86)	0.0132
1345-4 [GCGG]
0 copies	182 (93.8)	148 (87.6)	Ref.		Ref.
1 or 2 copies	12 (6.2)	21 (12.4)	0.46 (0.22–0.98)	0.0428	0.40 (0.17–0.95)	0.0379
12345-5 [GGCGG]
0 copies	183 (94.3)	149 (88.2)	Ref.		Ref.
1 or 2 copies	11 (5.7)	20 (11.8)	0.45 (0.21–0.96)	0.0400	0.41 (0.17–0.99)	0.0472

Haplotypes with total frequencies of less than 1 percent were excluded in table.

OR: odds ratio; CI: confidence interval; AMACR: (R)-alpha-methyl-CoA racemase.

*1: rs2278008; 2: rs34677; 3: rs2287939; 4: rs10941112; 5: rs3195676.

^aAdjusted for age, smoking quantity, alcohol drinking, and family history of prostate cancer.